Axsome Therapeutics vs. Moderna: Comparing Investments in Biotech Innovators
AXSM Axsome Therapeutics Inc
$141.69 -1.86%
View chart & analysis → - 1Axsome Therapeutics recorded a revenue growth rate of approximately 54% for the 12 months ended September 30, 2026.
- 2Moderna recorded revenue of approximately $2.5 billion for the 12 months ended September 30, 2026.
- 3Axsome Therapeutics appears to be an option with a conservative valuation, while Moderna trades at a high premium.
So what's the key point?
Axsome Therapeutics recorded a revenue growth rate of approximately 54% for the 12 months ended September 30, 2026.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.